CSIMarket Company Name, Ticker, Customers, else..
 
Century Therapeutics inc   (NASDAQ: IPSC)
 
Price: $2.0500 $0.02 1.235%
Day's High: $2.059999942779541 Week Perf: -5.53 %
Day's Low: $ 1.97 30 Day Perf: 1.49 %
Volume (M): 373,330 52 Wk High: $ 3.04
Volume (M$): $ 0 52 Wk Avg: $1.64
Open: $2.00 52 Wk Low: $0.44



 Market Capitalization (Millions $) 397
 Shares Outstanding (Millions) 193
 Employees 78
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1

Business Description


Century Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing genetically engineered immune cells for cancer therapy. The company utilizes induced pluripotent stem cells (iPSCs) to create immune cells, such as T cells and natural killer (NK) cells, that have enhanced anti-tumor properties. By reprogramming these cells, Century aims to improve their efficacy and safety for use in cancer treatment. Their ultimate goal is to develop off-the-shelf cell therapies that can be readily available to treat a wide range of tumors. Century Therapeutics is based in Philadelphia, Pennsylvania, and was founded in 2018.


   Company Address: 25 N 38th Street, 11th Floor Philadelphia 19104 PA
   Company Phone Number: 817-5790   Stock Exchange / Ticker: NASDAQ IPSC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA   -5.92%    
EXEL        0.16% 
GILD   -0.27%    
IMCR   -0.79%    
MRNA        1.04% 
RGNX        17.94% 
• View Complete Report
   



Product Service News

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Published Thu, Nov 13 2025 12:50 PM UTC

Century Therapeutics Unveils Ambitious Beta Islet Program Aiming to Transform Type 1 Diabetes TreatmentPharmaceutical innovation is often heralded by a blend of promise and peril, especially in a field as complex as diabetes research. On November 13, 2025, Century Therapeutics, Inc., a Philadelphia-based biotechnology firm, took a significant step in this landscape with the...
Clinical Study

Century Therapeutics Pioneering the Future of iPSC-Derived Cell Therapies at ASGCT 2025,

Published Tue, Apr 29 2025 7:19 AM UTC

Pioneering Advances in Cell Therapy: Century Therapeutics at the Forefront of InnovationIn a landscape where pioneering science meets unmet clinical needs, Century Therapeutics, Inc. a notable player in biotechnology, has become a significant torchbearer. The company s latest announcements showcase its relentless pursuit of therapeutic breakthroughs, particularly in the rea...
Product Service News

Century Therapeutics Innovative Cell Therapy, CNTY-101, Shows Promising Safety Profile and Outpatient Feasibility in...

Published Mon, Jun 3 2024 11:00 AM UTC

Century Therapeutics, a leading cell therapy company, has presented promising interim results from their Phase 1 ELiPSE-1 study at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). The results highlight the safety and efficacy of CNTY-101, a cutting-edge investigational cell therapy for the treatment of hematologic malignancies.During the ongoing d...
Merger and Acquisition

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics.

Published Thu, Apr 11 2024 11:00 AM UTC

Century Therapeutics, a leading biotechnology company in the field of autoimmune diseases, is making significant strides in its pursuit of additional regulatory filings for its cutting-edge iPSC derived iNK cell therapy, CNTY-101. The company s recent CALiPSO-1 trial in systemic lupus erythematosus (SLE) has shown promising results, prompting Century Therapeutics to explore ...
Clinical Study

Century Therapeutics Showcases CAR iNK Therapy Potential Amid Revenue Decline

Published Sat, Dec 9 2023 5:00 PM UTC



Philadelphia-based biotechnology company Century Therapeutics Inc. recently presented initial data from the CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The results highlight the potential for a multi-dosing strategy for CAR iNK therapy enabled by allo-evasion edits. In addition, the therapy was found to be generally well tolerated in a high-risk...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.5
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.94
Working Capital Ratio 10.25
Leverage Ratio (MRQ) 0.23
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.11 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.7 $
Book Value 1.37 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,381,859
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.